May 10 (Reuters) - Novavax Inc NVAX.O :
* NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR COMBINATION INFLUENZA AND COVID-19 VACCINE CANDIDATE
* NOVAVAX INC - NANOFLU/NVX-COV2373 COMBINATION VACCINE DEMONSTRATED POSITIVE IMMUNE RESPONSES TO BOTH INFLUENZA AND SARS-COV-2
* NOVAVAX INC - CLINICAL STUDIES OF COMBINATION VACCINE ARE EXPECTED TO BEGIN BY END OF YEAR